Highly active antiretroviral therapy–related immune recovery in AIDS patients with cytomegalovirus retinitis11The authors do not have any proprietary interest in any product mentioned in the text.

Cytomegalovirus (CMV)–Specific CD4+T Lymphocyte Immune Function in Long‐Term Survivors of AIDS‐Related CMV End‐Organ Disease Who Are Receiving Potent Antiretroviral Therapy

“…Now, with HAART-related increases in absolute CD4 ϩ T lymphocyte counts to 1100 cells/mL, anti-CMV therapy can be discontinued with little risk of short-term retinitis progression [4][5][6][7]. Long-term outcomes for such patients are unknown.…”

Sustained release of ganciclovir and foscarnet from biodegradable scleral plugs for the treatment of cytomegalovirus retinitis

“…The major limitation of the device design is the limited pharmaceutical load which is mainly restricted by the small plug size and requirement of pharmaceutical/polymer ratio to maintain desired drug release profile. However, in the HAART era, the major purpose of intravitreal anti-CMV therapy is to cover the immune deficiency window period before the accomplishment of satisfactory antiretroviral effect [33,34]. This greatly reduces the time period of anti-CMV therapy as compared with that was required in pre-HAART era.…”

Therapy and prevention of cytomegalovirus retinitis

“…The positive effects of HAART on the CD4 T cell, and HAART's ability to partially restore the T-cell repertoire even in advanced AIDS [11••], has led to a previously unthinkable practice of discontinuing secondary prophylaxis for CMV retinitis. Table 3 summarizes data from separate sources [36][37][38][39][40][41][42][43][44][45][46][47] that cumulatively studied 180 HAART recipients with healed CMV retinitis who discontinued specific anti-CMV therapy and were followed-up for a mean of 5 to 25 months. The CD4 cell counts at the time of stopping specific anti-CMV therapy ranged from as low as 60 to as high as 770 cells/ mm 3 .…”